世界の肝臓癌治療薬市場 - 成長、動向、予測
Liver Cancer Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
|世界の肝臓癌治療薬市場 - 成長、動向、予測|
発行: Mordor Intelligence LLP
ページ情報: 英文 115 Pages
The liver cancer therapeutics market is expected to register a CAGR of nearly 8.00% during the forecast period, 2019-2024. The major factors for the growth of the liver cancer therapeutics market include the rising prevalence of liver cancer, increasing R&D investments for the development of novel therapies, and government initiatives to increase cancer awareness.
Liver cancer is cancer that begins in the liver cells and the therapies used in the treatment of liver cancer are covered under this report. The market is segmented by type, therapy, and geography.
Hepatocellular Carcinoma is the Segment by Type is expected to be the Fastest Growing Segment
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, which mostly occurs in people suffering from chronic liver diseases, like cirrhosis. Hepatocellular carcinoma is one of the major causes leading to cancer-related deaths worldwide. It is observed that the Asian and African countries have higher incidence rates of hepatocellular carcinoma than the developed world, due to the disparity in the major risk factors causing hepatocellular carcinoma, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infection in those regions. As per the data published by the National Organization for Rare Diseases (NORD), there are approximately six new cases of HCC per every 100,000 people in the general population of the United States. With the increase in the incidence of hepatocellular carcinoma, there is expected to be a huge demand for the liver cancer therapeutics. Hence, the rising incidence of cancer and high unmet medical needs are the major factors that drive the market in the forecast period.
North America is Expected to Dominate the Market
North America is expected to dominate the market, due to the presence of better healthcare infrastructure and rising geriatric population. According to the estimates of American Society of Clinical Oncology, there are 42,220 adults who are diagnosed with liver cancer in the United States in 2018, (of which there are 30,610 men and 11,610 women). According to the Center for Disease Control and Prevention (CDC), 32,908 new cases of liver cancer were identified in 2015 in the United States, of which, the death toll was 25,760. It is observed that for every 100,000 people, 8 new liver cancer cases, and 7 deaths were registered. Hence, the incidence of liver cancer in the United States has increased during 2015-2018. This is leading to an increasing demand for liver cancer treatment, which, in turn, is driving the market in the forecast period.
The market studied is a consolidated market, owing to the presence of a few major market players. Market players are focusing on R&D to bring innovative treatments for the treatment of liver cancer. Some of the market players are ArQule Inc., Bayer AG, Bristol-Myers Squibb Company, Celsion Corp., Eisai Inc., Exelixis Inc, F. Hoffmann-La Roche Ltd, and Merck & Co. Inc.